Dr. Kent Berridge
speaker
525 appearances
1 recordings
1 series
first heard Aug 2026
last heard 4 Aug
Dr. Kent Berridge’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Aug 2026 with 1.
Appearances
And I think many people could resonate to that.
Um, encouraging, um, both for weight loss and for potentially giving up drug use.
It's better than anything that's come down the pike previously.
So, you know, there's anecdotal reports already.
There are some studies already, um, that suggests it's reducing opioid cravings or alcohol craving.
It's not a magic bullet.
It doesn't work for everybody and neither does it help weight loss for everybody, but it helps, um,
A number, a good number.
And it helps more than previous medications.
So I'd say it's very encouraging so far.
No, absolutely.
And animal experiments, neuroscience experiments support it absolutely too.
The drugs, the GLP-1 agonists, they're acting on hunger satiety centers in the brainstem and hypothalamus, but they're also acting in this dopamine system, the mesolimbic dopamine system.
Even micro injections of droplets of these drugs into the dopamine system of rats will suppress their craving for food and suppress their craving for drugs.
preference and things of that sort.
So it's acting directly in the mesolimbic system when it can get there.
Some of these GLP-1 agonists are able to penetrate the blood brain barrier and get to all of these targets.
Other GLP-1 agonists are not so good at getting to
through the blood brain barrier, so they can't get all the brain, but they still can get to the brainstem and hypothalamic little parts that don't have a blood brain barrier.
And those parts seem to also modulate and suppress the dopamine system's response to these cues.
Showing 241–260 of 525 · page 13 of 27
← Previous
Next →